Royal Bank of Canada’s Endocyte, Inc. Common Stock ECYT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-5,870
| Closed | -$105K | – | 7465 |
|
|
2018
Q3 | $105K | Sell |
5,870
-1,180
| -17% | -$20.3K | ﹤0.01% | 4831 |
|
|
2018
Q2 | $97K | Hold |
7,050
| – | – | ﹤0.01% | 4823 |
|
|
2018
Q1 | $65K | Sell |
7,050
-5,832
| -45% | -$32.2K | ﹤0.01% | 4928 |
|
|
2017
Q4 | $55K | Sell |
12,882
-5,728
| -31% | -$27.3K | ﹤0.01% | 5137 |
|
|
2017
Q3 | $27K | Sell |
18,610
-79,530
| -81% | -$111K | ﹤0.01% | 5805 |
|
|
2017
Q2 | $147K | Sell |
98,140
-24,821
| -20% | -$53.3K | ﹤0.01% | 4553 |
|
|
2017
Q1 | $316K | Sell |
122,961
-12,885
| -9% | -$29.8K | ﹤0.01% | 4005 |
|
|
2016
Q4 | $346K | Sell |
135,846
-6,300
| -4% | -$18.1K | ﹤0.01% | 4076 |
|
|
2016
Q3 | $440K | Sell |
142,146
-9,019
| -6% | -$28.1K | ﹤0.01% | 3819 |
|
|
2016
Q2 | $486K | Sell |
151,165
-47
| -0% | -$172 | ﹤0.01% | 3725 |
|
|
2016
Q1 | $469K | Sell |
151,212
-10,719
| -7% | -$35K | ﹤0.01% | 3701 |
|
|
2015
Q4 | $650K | Sell |
161,931
-27,891
| -15% | -$128K | ﹤0.01% | 3508 |
|
|
2015
Q3 | $869K | Sell |
189,822
-2,824
| -1% | -$14.8K | ﹤0.01% | 2991 |
|
|
2015
Q2 | $1M | Buy |
192,646
+111,702
| +138% | +$670K | ﹤0.01% | 2915 |
|
|
2015
Q1 | $507K | Sell |
80,944
-9,493
| -10% | -$54.8K | ﹤0.01% | 3492 |
|
|
2014
Q4 | $569K | Sell |
90,437
-965
| -1% | -$5.88K | ﹤0.01% | 3432 |
|
|
2014
Q3 | $556K | Buy |
91,402
+1,085
| +1% | +$7.41K | ﹤0.01% | 3364 |
|
|
2014
Q2 | $595K | Sell |
90,317
-11,568
| -11% | -$130K | ﹤0.01% | 3258 |
|
|
2014
Q1 | $2.43M | Buy |
101,885
+21,459
| +27% | +$311K | ﹤0.01% | 2114 |
|
|
2013
Q4 | $859K | Buy |
80,426
+34,166
| +74% | +$377K | ﹤0.01% | 2965 |
|
|
2013
Q3 | $616K | Buy |
46,260
+5,188
| +13% | +$82K | ﹤0.01% | 3210 |
|
|
2013
Q2 | $539K | Buy |
+41,072
| New | +$554K | ﹤0.01% | 3097 |
|
Other funds holding ECYT
Royal Bank of Canada's ECYT Position: Q4 2018 in Review
Royal Bank of Canada sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 5,870 shares — an estimated $105K sold.
Royal Bank of Canada first reported a position in ECYT in Q2 2013 and held it in 22 quarters. The position peaked at $2.43M in Q1 2014. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.
- Royal Bank of Canada reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
- Royal Bank of Canada sold 5,870 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $105K.
- Royal Bank of Canada first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 22 quarters.
- Royal Bank of Canada's Endocyte, Inc. Common Stock position peaked at $2.43M in Q1 2014.
- 2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.
Based on Royal Bank of Canada's 13F filing for Q4 2018, filed 14 Feb 2019.